ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO199

Possible Contribution of Vascular Endothelial Growth Factor A (VEGF-A) to the Pathogenesis of Membranous Nephropathy (MN)

Session Information

Category: Nephrology Education

  • 1302 Fellows and Residents Case Reports

Authors

  • Matsumoto, Ayumi, Osaka University Graduate School of Medicine, Suita, Japan
  • Matsui, Isao, Osaka University Graduate School of Medicine, Suita, Japan
  • Namba, Tomoko, Osaka University Graduate School of Medicine, Suita, Japan
  • Sakaguchi, Yusuke, Osaka University Graduate School of Medicine, Suita, Japan
  • Mizui, Masayuki, Osaka University Graduate School of Medicine, Suita, Japan
  • Hamano, Takayuki, Osaka University Graduate School of Medicine, Suita, Japan
  • Isaka, Yoshitaka, Osaka University Graduate School of Medicine, Suita, Japan
Background

Autoantibody against thrombospondin type-1 domain-containing 7A (THSD7A) is responsible for primary MN, but the mechanisms how is THSD7A-expression controlled and how is THSD7A recognized by the immune system remain uncertain.

Methods

Two cases of THSD7A-associated MN accompanying subcutaneous tumors were transferred to our hospital. Hypereosinophilia was evident in both cases. Histological analyses of forehead tumors of Case 1 revealed that the tumors were formed by swollen arteries. The arteries were nearly occluded due to small vessels lined by CD31-positive plump endothelial cells, which were surrounded by eosinophils. These findings indicated that the patient suffered from intra-arterial angiolymphoid hyperplasia with eosinophilia (ALHE). The right axillary tumor of Case 2 indicated that Case 2 also suffered from ALHE. Plasma VEGF-A before the initiation of prednisolone therapy was elevated to 109 pg/mL in Case 1 (normal level: 42 ± 20 pg/mL). Serum level of IL-5, a cytokine that upregulates VEGF-A production and secretion by eosinophils, was also elevated to 15.5 pg/mL in Case 1 (normal level: <3.9 pg/mL). These parameters were not measured in Case 2. Flow cytometric analysis of peripheral blood revealed that a substantial number of the circulating eosinophils was positive for VEGF-A in Case 1, and eosinophils infiltrated into the ALHE tumor were also positive for VEGF-A in both cases. Prednisolone therapy dramatically decreased the number of VEGF-positive eosinophils and plasma VEGF-A levels (57.3 pg/mL). We found that plump endothelial cells in ALHE strongly expressed THSD7A in both cases. VEGF-A upregulated THSD7A expression in a dose-dependent manner in cultured human umbilical-vein endothelial cells. Furthermore, double-positive cells for THSD7A and CD83, a molecule involved in antigen-presentation activity, surrounded the proliferated small vessels. These findings suggested that VEGF-A-induced THSD7A was presented to the immune system at ALHE foci.

Conclusion

Our study clearly demonstrated that VEGF-A induced THSD7A expression. The existence of THSD7A/CD83 double-positive cells in ALHE tumors suggested that THSD7A was immunized at ALHE foci. Therefore, VEGF-A-induced THSD7A-expression outside of the kidney plays important roles in MN pathogenesis.

Funding

  • Private Foundation Support